Free Trial

Nature's Sunshine Products (NASDAQ:NATR) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Nature's Sunshine Products logo with Medical background

Key Points

  • Nature's Sunshine Products' stock (NASDAQ:NATR) has recently crossed above its 200-day moving average, reaching a high of $15.64 and last trading at $15.51.
  • Analyst reports show a consensus rating of "Moderate Buy" for NATR, with price targets increasing from $21.00 to $22.00, despite one analyst rating it as a "Hold."
  • Insider selling has been notable, with executives like Nathan G. Brower and Bryant J. Yates reducing their holdings, indicating potential concern among management about the stock's future performance.
  • MarketBeat previews top five stocks to own in November.

Shares of Nature's Sunshine Products, Inc. (NASDAQ:NATR - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.60 and traded as high as $15.64. Nature's Sunshine Products shares last traded at $15.51, with a volume of 59,368 shares.

Analyst Ratings Changes

NATR has been the subject of several research analyst reports. Canaccord Genuity Group upped their price objective on shares of Nature's Sunshine Products from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Weiss Ratings reiterated a "hold (c)" rating on shares of Nature's Sunshine Products in a report on Saturday, September 27th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.50.

Read Our Latest Research Report on NATR

Nature's Sunshine Products Price Performance

The company has a market capitalization of $273.60 million, a price-to-earnings ratio of 20.96 and a beta of 1.12. The stock has a 50 day moving average price of $16.23 and a two-hundred day moving average price of $14.60.

Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.35 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.19. Nature's Sunshine Products had a return on equity of 10.19% and a net margin of 3.06%.The firm had revenue of $114.75 million during the quarter, compared to analyst estimates of $113.10 million. Nature's Sunshine Products has set its FY 2025 guidance at EPS.

Insider Transactions at Nature's Sunshine Products

In related news, EVP Nathan G. Brower sold 9,996 shares of the firm's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $16.54, for a total value of $165,333.84. Following the sale, the executive vice president directly owned 48,277 shares of the company's stock, valued at $798,501.58. This trade represents a 17.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Bryant J. Yates sold 4,672 shares of the firm's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $16.71, for a total value of $78,069.12. Following the transaction, the executive vice president owned 97,498 shares of the company's stock, valued at $1,629,191.58. This trade represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,668 shares of company stock worth $409,803 in the last 90 days. Corporate insiders own 4.70% of the company's stock.

Institutional Trading of Nature's Sunshine Products

Several hedge funds have recently made changes to their positions in NATR. Kennedy Capital Management LLC raised its stake in shares of Nature's Sunshine Products by 37.2% during the 2nd quarter. Kennedy Capital Management LLC now owns 589,636 shares of the company's stock valued at $8,721,000 after purchasing an additional 160,002 shares during the period. Acadian Asset Management LLC lifted its holdings in Nature's Sunshine Products by 17.9% in the 2nd quarter. Acadian Asset Management LLC now owns 558,169 shares of the company's stock worth $8,241,000 after buying an additional 84,636 shares during the period. Skylands Capital LLC lifted its holdings in Nature's Sunshine Products by 1.7% in the 1st quarter. Skylands Capital LLC now owns 431,800 shares of the company's stock worth $5,419,000 after buying an additional 7,209 shares during the period. AWM Investment Company Inc. bought a new position in shares of Nature's Sunshine Products in the 2nd quarter worth approximately $5,176,000. Finally, American Century Companies Inc. increased its position in Nature's Sunshine Products by 9.6% during the 2nd quarter. American Century Companies Inc. now owns 334,156 shares of the company's stock valued at $4,942,000 after buying an additional 29,153 shares in the last quarter. 79.40% of the stock is currently owned by institutional investors.

Nature's Sunshine Products Company Profile

(Get Free Report)

Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nature's Sunshine Products Right Now?

Before you consider Nature's Sunshine Products, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nature's Sunshine Products wasn't on the list.

While Nature's Sunshine Products currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.